Browsing by Author "Cabrera, E"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Synthesis of 11,12-epoxydrim-8,12-en-11-ol, 11,12-diacetoxydrimane, and warburganal from (-)-sclareol
    (AMER CHEMICAL SOC, 1999) Barrero, AF; Cortes, M; Manzaneda, EA; Cabrera, E; Chahboun, R; Lara, M; Rivas, AR
    The first syntheses are reported for recently isolated drimanes 11,12-epoxydrim-8,12-en-11-ol (2) and 11,12-diacetoxydrimane (3), from (-)-sclareol (1). Furthermore, two efficient new routes to the potent bioactive warburganal (4) starting also from 1 are described.
  • No Thumbnail Available
    Item
    t(1;5)(q23;q33) in a patient with high-risk B-lineage acute lymphoblastic leukemia
    (1996) Barriga, F; Bertin, P; Legues, E; Risueno, C; Andrade, W; Cabrera, E; Grebe, G
    The t(1;5)(q23;q33) is a rare genetic anomaly that was reported previously in two infants with a myeloproliferative disorder and eosinophilia and in one adult patient with acute nonlymphocytic leukemia (ANLL). A 13-year-old boy with high-risk early pre-B acute lymphoblastic leukemia (ALL) who presented to our institution carried the t(1;5)(q23;q33). He had an initial blast count of 230 x 10(9)/L and responded poorly to prednisone. Complete remission ICR) was achieved, and he had a bone marrow (BM) relapse 3 months after despite intensive consolidation therapy He underwent allogeneic BM transplantation (BMT) from a human leukocyte antigen (HLA)-identical sibling in early relapse with total body irradiation (TBI) and cyclophosphamide conditioning. He had a short second CR with a central nervous system (CNS) relapse on day +106 after BMT. Two of the previously reported patients also did not respond to chemotherapy. The t(1;5)(q23;q33) appears to be a rare lineage nonspecific anomaly related to hematologic malignancies that are resistant to current therapy.